Onconetix, Inc. Increase (Decrease) in Accrued Liabilities
Onconetix, Inc. (ONCO) reported Increase (Decrease) in Accrued Liabilities of -$91.09 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- Onconetix, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$28.55K.
- Onconetix, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$62.54K, a 123.18% decline year-over-year.
- Onconetix, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$142.15K.
- Onconetix, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$427.93K.
- Onconetix, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$580.03K.
- Onconetix, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$1.13M.
- Onconetix, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$942.08K, a 154.15% decline from fiscal 2022.
- Onconetix, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $1.74M, a 114.99% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$28.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$91.09K 10-Q · filed 2026-08-13 | -$233.24K derived: sum of 3 quarters · filed 2026-08-13 | -$661.17K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$62.54K 10-Q · filed 2026-05-13 | -$204.69K derived: sum of 2 quarters · filed 2026-05-13 | -$632.62K derived: sum of 3 quarters · filed 2026-05-13 | -$912.35K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$142.15K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$570.08K derived: sum of 2 quarters · filed 2026-03-13 | -$849.81K derived: sum of 3 quarters · filed 2026-08-13 | -$580.03K 10-K · filed 2026-03-13 | |
| 2025-09-30 | -$427.93K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$707.66K derived: sum of 2 quarters · filed 2026-08-13 | -$437.88K 10-Q · filed 2025-11-13 | -$494.15K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$279.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$9.95K 10-Q · filed 2026-08-13 | -$66.22K derived: sum of 3 quarters · filed 2026-08-13 | -$245.77K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $269.78K 10-Q · filed 2026-05-13 | $213.51K derived: sum of 2 quarters · filed 2026-05-13 | $33.96K derived: sum of 3 quarters · filed 2026-05-13 | -$597.97K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$56.27K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$235.82K derived: sum of 2 quarters · filed 2026-03-13 | -$867.75K derived: sum of 3 quarters · filed 2026-03-13 | -$1.13M 10-K · filed 2026-03-13 | |
| 2024-09-30 | -$179.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$811.48K derived: sum of 2 quarters · filed 2025-11-13 | -$1.07M 10-Q · filed 2025-11-13 | -$1.04M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$631.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$893.23K 10-Q · filed 2025-08-14 | -$858.43K derived: sum of 3 quarters · filed 2025-08-14 | -$845.98K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$261.30K 10-Q · filed 2025-06-12 | -$226.51K derived: sum of 2 quarters · filed 2025-06-12 | -$214.06K derived: sum of 3 quarters · filed 2025-06-12 | -$989.07K derived: sum of 4 quarters · filed 2025-06-12 | |
| 2023-12-31 | $34.80K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | $47.24K derived: sum of 2 quarters · filed 2025-06-02 | -$727.76K derived: sum of 3 quarters · filed 2025-06-02 | -$942.08K 10-K · filed 2025-06-02 | |
| 2023-09-30 | $12.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-10 | -$762.56K derived: sum of 2 quarters · filed 2024-12-10 | -$976.87K 10-Q · filed 2024-12-10 | -$2.00M derived: sum of 4 quarters · filed 2024-12-10 | |
| 2023-06-30 | -$775.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-29 | -$989.32K 10-Q · filed 2024-08-29 | -$2.01M derived: sum of 3 quarters · filed 2024-08-29 | -$473.08K derived: sum of 4 quarters · filed 2024-08-29 | |
| 2023-03-31 | -$214.31K 10-Q · filed 2024-05-20 | -$1.24M 10-Q · filed 2023-05-12 | -$1.24M derived: sum of 2 quarters · filed 2024-05-20 | $301.93K derived: sum of 3 quarters · filed 2024-05-20 | $628.88K derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $516.24K derived: sum of 2 quarters · filed 2024-04-11 | $843.19K derived: sum of 3 quarters · filed 2024-04-11 | $1.74M 10-K · filed 2024-04-11 | |
| 2022-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $1.86M derived: sum of 2 quarters · filed 2023-11-17 | $2.76M 10-Q · filed 2023-11-17 | $3.07M derived: sum of 4 quarters · filed 2023-11-17 | |
| 2022-06-30 | $326.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-10-20 | $1.22M 10-Q · filed 2023-10-20 | $1.54M derived: sum of 3 quarters · filed 2023-10-20 | $1.60M derived: sum of 4 quarters · filed 2023-10-20 | |
| 2022-03-31 | $896.66K 10-Q · filed 2023-05-12 | $1.21M derived: sum of 2 quarters · filed 2023-05-12 | $1.27M derived: sum of 3 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $313.17K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $374.55K derived: sum of 2 quarters · filed 2023-03-09 | $809.28K 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $61.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $496.11K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $434.73K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |